2023, Number 4
Costs of polypharmacy in the elderly with type 2 diabetes mellitus
Language: English
References: 18
Page: 397-403
PDF size: 349.66 Kb.
ABSTRACT
Objective: Calculate the cost of polypharmacy in elderly patients with DM2.Method: 104 clinical records of the basic nuclei of a General Hospital in Tabasco of elderly patients with DM2 were selected. The consumption of drugs and present pathologies were recorded; the cost of drugs and the demand for health services were estimated.
Results: It was found that 50% of the patients suffer from arterial hypertension in addition to DM2; 69.23% use 6 drugs; 28.85% of the patients came to 6 consultations; the annual per-ception of health services personnel was $3,652,140.2 MXN for doctors, $2,250,853 MXN for nursing, and $290,205.60 MXN for pharmacy personnel.
Conclusion: Promoting primary care is essential to reduce the incidence of chronic-degenerative diseases that, together with aging, lead to polypharmacy and a higher cost of care per patient.
REFERENCES
León-Vázquez M, Seefoó-Jarquin P, Portillo-García Z, Ballinas-Irvin YR, Díaz-Álvarez G, Fonseca-Basurto D. Polifarmacia y cumplimiento terapéutico en el adulto mayor con diabetes mellitus tipo 2 e hipertensión arterial. Med Gen Fam. 2021;10(6):272–7. Available from: https://mgyf.org/polifarmacia-y-cumplimiento-terapeutico-en-el-adulto-mayor-con-diabetes-mellitus-tipo-2-e-hipertension-arterial/
Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, et al. Encuesta Nacional de Salud y Nutrición 2021 sobre COVID-19. Resultados nacionales. Cuernavaca, México: Inst Nac Salud Public, 2022 [Internet]. 2022 [cited 2023 Apr 7]. Available from: https://www.insp.mx/resources/images/stories/2022/docs/220801_Ensa21_digital_29julio.pdf
Informe Trimestral de Vigilancia Epidemiológica Hospitalaria Diabetes Mellitus Tipo 2 Corte al 03 de abril del 2023 Dirección de Vigilancia Epidemiológica de Enfermedades No Transmisibles. 2023 [cited 2023 Apr 20]. Available from: https://www.gob.mx/cms/uploads/attachment/file/822041/SVEHDMT2_1ETRIM_2023.pdf
Sosa-Rubí SG, Contreras-Loya D, Pedraza-Arizmendi D, Chivardi-Moreno C, Alarid-Escudero F, López-Ridaura R, et al. Cost-effectiveness analysis of a multidisciplinary health-care model for patients with type-2 diabetes implemented in the public sector in Mexico: A quasi-experimental, retrospective evaluation. Diabetes Res Clin Pract. 2020;167:108336. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010712/
Pérez-Lozano DL, Camarillo-Nava VM, Juárez-Zepeda TE, Andrade-Pineda JE, Lucho-Gutiérrez ZM, Reyes-Pacheco JA et al. Costo-efectividad del tratamiento de la diabetes mellitus tipo 2 en México. Rev Med Inst Mex Seguro Soc. 2023;61(2):172-80. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396055/
Picó-Guzmán FJ, Martínez-Montañez OG, Ruelas-Barajas E, Hernández-Ávila M. Estimación del impacto económico por complicaciones cardiovasculares y de diabetes mellitus 2019-2028. Rev Med Inst Mex Seguro Soc. 2022 [cited july 11 2023]. Available from: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/4962